<DOC>
	<DOCNO>NCT00562172</DOCNO>
	<brief_summary>Primary objective : To compare long-term glycemic control preservation beta cell function basal insulin sulfonylurea add metformin early Type 2 Diabetes Mellitus patient Secondary objective : To assess change insulin resistance , microvascular complication incidence , patient satisfaction treatment</brief_summary>
	<brief_title>Insulin Glargine ( Lantus ) v Sulfonylurea ( SU ) BETA Cell Function ( BETA Study )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>List Inclusion Type 2 Diabetes Mellitus patient metformin monotherapy 7 % ≤ HbA1c ≤ 12 % 20 kg/m² ≤BMI ≤ 35 kg/m² Diabetes duration : least 6 month Type 1 Diabetes Mellitus patient Clinical evidence active liver disease , serum Alanine AminoTransferase 3 time upper limit normal range Serum creatinine : 1.5 mg/dl male , 1.4 mg/dl female Acute chronic metabolic acidosis , include diabetic ketoacidosis History alcohol substance abuse Pregnancy use contraceptive childbearing aged woman Known hypersensitivity Lantus , SU metformin Any disease condition opinion investigator may interfere completion study The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>